PYC

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

Retrieved on: 
Monday, November 13, 2023

PERTH, Australia and SAN FRANCISCO, Nov. 13, 2023 /PRNewswire/ -- PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].

Key Points: 
  • The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective.
  • PYC-003 is the fourth program in the Company's development pipeline – joining three other first-in-class RNA drug candidates with disease-modifying potential currently progressing into or through human trials.
  • An Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to enable the commencement of human trials for this drug candidate is planned for H2 2024.
  • A New Drug Application in support of this candidate could be submitted following two clinical trials rather than the conventional three[11].

US FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM

Retrieved on: 
Friday, August 11, 2023

PERTH, Australia and SAN FRANCISCO, Aug. 11, 2023 /PRNewswire/ -- PYC Therapeutics Limited (ASX:PYC) today announces that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA).

Key Points: 
  • PERTH, Australia and SAN FRANCISCO, Aug. 11, 2023 /PRNewswire/ -- PYC Therapeutics Limited (ASX:PYC) today announces that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA).
  • The Fast Track process is "designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need" with Fast Track status "often leading to earlier drug approval and access by patients"[3].
  • Benefits of the Fast Track designation include:
    Increased frequency of meetings with the FDA to discuss the drug's development plan;
    Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met; and
    PYC will utilise the Fast Track designation to work with the FDA on advancing this important drug program towards patients on an accelerated timeline.
  • PYC's CEO Dr Rohan Hockings commented:

Life sciences industry's highest achievers celebrated at prestigious Awards ceremony

Retrieved on: 
Thursday, October 27, 2022

PERTH, Australia, Oct, 27, 2022 /PRNewswire/ -- Biotech's illustrious Industry Excellence Awards were announced today at the AusBiotech 2022 national conference in Perth – recognising outstanding contribution and achievement. The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards recognise innovative companies and individuals in Australia's world-class biotechnology, medical technology and healthcare sectors.

Key Points: 
  • The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards recognise innovative companies and individuals in Australia's world-class biotechnology, medical technology and healthcare sectors.
  • Dr Andrew Forrest AO and Nicola Forrest AO were also awarded the AusBiotech Life Sciences Legacy Award in recognition of their generous and active support of medical research and Australian life science innovation.
  • The discovery, development and commercialisation of biomedical research takes a global effort from diverse ecosystem including scientists, entrepreneurs, philanthropists and industry partners.
  • AusBiotech is a well-connected network of over 3,000 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), food technology and agricultural sectors.

ThermVac Develops Chemical Vapor Deposition Technologies for SiC, TaC, B4C and PYC

Retrieved on: 
Wednesday, January 5, 2022

This is in line with the increasing demand for high-temperature heat resistant CVD components from high-tech industries such as semiconductor, solar power, mobile phones, aerospace and defense.

Key Points: 
  • This is in line with the increasing demand for high-temperature heat resistant CVD components from high-tech industries such as semiconductor, solar power, mobile phones, aerospace and defense.
  • ThermVac has built in-house pilot CVD equipment that can raise the temperature up to 2,400C.
  • In response to clients' various CVD equipment requirements, it conducts process tests in advance using pilot equipment along with the overall design of CVD equipment.
  • Thereby it enhances equipment reliability as well as provides the customers with basic process recipes that are essential for initial equipment operation.

PYC Therapeutics Announces Upcoming Poster Presentations Highlighting Preclinical Data from its Ocular and Neurologic Development Programs at TIDES USA and OTS 2021

Retrieved on: 
Tuesday, September 21, 2021

The first poster will be presented at TIDES USA 2021, an Oligonucleotide and Peptide Therapeutics conference, taking place September 2030, 2021.

Key Points: 
  • The first poster will be presented at TIDES USA 2021, an Oligonucleotide and Peptide Therapeutics conference, taking place September 2030, 2021.
  • The second poster will be presented at the Oligonucleotide Therapeutics Society (OTS) 2021 Annual Meeting, taking place September 2629, 2021.
  • PYC's discovery and laboratory operations are located in Australia, and the Company's preclinical, clinical, regulatory and corporate operations are based in San Diego, California.
  • The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

PYC Therapeutics Invited to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Retrieved on: 
Wednesday, September 15, 2021

Sahm Nasseri, U.S. Chief Executive Officer of PYC, will present a corporate overview on Tuesday, September 21, 2021 at 4:35 p.m ET.

Key Points: 
  • Sahm Nasseri, U.S. Chief Executive Officer of PYC, will present a corporate overview on Tuesday, September 21, 2021 at 4:35 p.m ET.
  • Members of PYC's management team will also participate in one-on-one meetings with U.S biotech and life science investors.
  • PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines.
  • The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

PYC Therapeutics to Host Quarterly Investor Call on August 17 at 9 a.m. AWST | 11 a.m. AEST

Retrieved on: 
Wednesday, August 11, 2021

ET / 6 p.m. U.S. PT) to discuss corporate and pipeline updates.

Key Points: 
  • ET / 6 p.m. U.S. PT) to discuss corporate and pipeline updates.
  • PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines.
  • PYC's discovery and laboratory operations are located in Australia, and the Company's preclinical, clinical, regulatory and corporate operations are based in San Diego, California.
  • The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.